Expert insights on RSV vaccination: Protecting vulnerable high-risk older adults
25 Jun 2025
byProf. Ivan Hung, Department of Medicine, University of Hong Kong, Hong Kong; Prof. Lucy Morgan, University of Sydney and Macquarie University, Sydney, Australia
Respiratory syncytial virus (RSV) infection, especially in the elderly and older adults with one or more comorbidities, may lead to severe complications that require hospitalization, or even death. At the 2nd Hong Kong RSV Summit, Professor Ivan Hung of the Department of Medicine, University of Hong Kong, Hong Kong, and Professor Lucy Morgan of the University of Sydney and Macquarie University, Sydney, Australia, discussed efficacy and safety data of the recombinant adjuvanted RSVPreF3 vaccine and the importance of protecting the high-risk population ≥50 years of age against RSV infection and infection-associated risks.
